文献速递肾癌与肾肿瘤

接受一线治疗的肾细胞癌脑转移患者的结局:国际转移性肾细胞癌数据库联盟(IMDC)结果

Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
PubMed 文献 · Eur Urol · 2024-01-29

基于IMDC数据库分析4799例接受系统治疗的转移性肾细胞癌患者,其中389例(8.1%)在起始系统治疗时存在脑转移。脑转移患者预后显著差于无脑转移者;一线免疫肿瘤(IO)联合治疗和立体定向放疗或神经外科手术分别与更长的总生存期(OS)相关。

要点

  • 起始系统治疗时8.1%(389/4799)的转移性肾细胞癌患者存在脑转移。
  • 脑转移患者接受IO联合治疗的中位OS为32.7个月,优于TKI单药的20.6个月(p=0.019)。
  • 接受立体定向放疗或神经外科手术者中位OS为31.4个月,优于全脑放疗或不接受局部治疗的16.5个月(p=0.028)。

核心结论

  • 在转移性肾细胞癌脑转移患者中,强化系统治疗和局部治疗与更好的预后相关。
  • 原文结论指出需要进一步研究探索多模式策略的临床有效性。

研究设计与样本

  • 基于国际转移性肾细胞癌数据库联盟(IMDC)的数据分析,纳入4799例患者,其中389例(8.1%)在起始系统治疗时存在脑转移。

主要发现

  • 脑转移患者的中位OS:一线IO联合治疗为32.7个月(95%CI 22.3-未达到),TKI单药为20.6个月(95%CI 15.7-24.5),p=0.019。
  • 脑转移患者的中位OS:立体定向放疗或神经外科手术为31.4个月(95%CI 22.3-37.5),全脑放疗或不接受局部治疗为16.5个月(95%CI 10.2-21.1),p=0.028。
  • 多变量分析中,IO为基础方案与更长OS独立相关(HR 0.49,95%CI 0.25-0.97;p=0.040)。
  • 多变量分析中,立体定向放疗或神经外科手术与更长OS独立相关(HR 0.48,95%CI 0.29-0.78;p=0.003)。
  • 多变量分析中,IMDC预后良好或中危与更长OS独立相关(HR 0.40,95%CI 0.24-0.66;p<0.001)。

临床怎么用

  • 原文结论指出,强化系统治疗和局部治疗与该脑转移人群更好的预后相关,并建议进一步研究探索多模式策略的临床有效性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated with longer median overall survival (OS; 32.7 mo, 95% confidence interval [CI] 22.3-not reached) versus tyrosine kinase inhibitor monotherapy (20.6 mo, 95% CI 15.7-24.5; p = 0.019), as were intensive focal therapies with stereotactic radiotherapy or neurosurgery (31.4 mo, 95% CI 22.3-37.5) versus whole-brain radiotherapy alone or no focal therapy (16.5 mo, 95% CI 10.2-21.1; p = 0.028). On multivariable analysis, IO-based regimens (HR 0.49, 95% CI 0.25-0.97; p = 0.040) and stereotactic radiotherapy or neurosurgery (HR 0.48, 95% CI 0.29-0.78; p = 0.003) were independently associated with longer OS, as was IMDC favorable or intermediate risk (HR 0.40, 95% CI 0.24-0.66; p < 0.001). Intensive systemic and focal therapies were associated with better prognosis in this population. Further studies should explore the clinical effectiveness of multimodal strategies. PATIENT SUMMARY: In a large group of patients with advanced kidney cancer, we found that 8.1% had brain metastases when starting systemic therapy. Patients with brain metastases had significantly poorer prognosis than those without brain metastases. Receipt of combination immunotherapy, stereotactic radiotherapy, or neurosurgery was associated with longer overall survival.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Takemura K, Lemelin A, Ernst MS, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2024. PMID: 38290965. doi:10.1016/j.eururo.2024.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。